CJC-1295: Research Overview

The short version

CJC-1295 is a synthetic analog of growth hormone-releasing hormone, the signaling peptide that tells the pituitary to release GH. It was engineered to last much longer than the natural molecule — days instead of minutes — by making it harder for enzymes to break it down, and, in one variant, by tethering it to serum albumin (the most abundant protein in blood) so it hitchhikes for days before releasing.

The key things to know before going further: CJC-1295 has never been approved by the FDA or any major regulator for human use. The human evidence base is limited to a handful of early pharmacokinetic studies in small groups of healthy adults. The original drug-development program was discontinued. The FDA's Pharmacy Compounding Advisory Committee reviewed — and did not recommend — CJC-1295 for the 503A compounding bulks list in 2024, citing immunogenicity and other safety concerns. And it is banned at all times in competitive sport.

This page follows the published evidence and names the gaps honestly.

What it is

CJC-1295 is built on the first 29 residues of human growth hormone-releasing factor (hGRF(1-29)) with four amino-acid substitutions: D-Ala at position 2, Gln at 8, Ala at 15, and Leu at 27. These substitutions stabilize the alpha-helical structure and block cleavage by dipeptidyl peptidase IV (DPP-IV) and other proteases, dramatically extending plasma stability relative to native GHRH.

The compound exists in two pharmacologically distinct forms that are routinely — and consequentially — confused:

• CJC-1295 with DAC (Drug Affinity Complex): A C-terminal lysine carries a maleimidopropionyl linker that reacts with the free thiol on Cys34 of circulating albumin, forming a covalent peptide-albumin conjugate. Estimated plasma half-life: 5.8–8.1 days ^[10]. A single dose can keep GH and IGF-1 elevated for one to nearly two weeks.
• CJC-1295 without DAC (Modified GRF 1-29): Retains the four substitutions but lacks the albumin-binding moiety. Short-acting — hours, not days. Community discussions often treat these as interchangeable; they are not. The long-duration IGF-1 elevation, fluid retention, and blood-sugar effects reported with the DAC form are largely attributable to its prolonged pharmacokinetics.

CJC-1295 was identified using high-resolution LC-MS/MS as the active ingredient in an unknown 'GHRH' pharmaceutical preparation seized in an anti-doping context ^[8] — an early data point in the compound's story that tells you something about its distribution outside regulated channels.

How it works

Like sermorelin and tesamorelin, CJC-1295 binds the GHRH receptor on anterior-pituitary somatotrophs and activates the Gs/cAMP/PKA signaling cascade, driving synthesis and pulsatile release of endogenous GH, which in turn raises hepatic IGF-1 ^[1]. The mechanism is shared across the GHRH-analog class; what CJC-1295 adds is duration.

A pivotal human pharmacokinetic study in healthy adults (ages 21-61) found that a single subcutaneous dose produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more, and 1.5- to 3-fold increases in IGF-1 for 9-11 days. After multiple doses, IGF-1 remained above baseline for up to 28 days. Estimated half-life: 5.8-8.1 days ^[10]. That is a very different pharmacokinetic profile from native GHRH or sermorelin, both of which are short-acting.

Importantly, a separate study in healthy men ages 20-40 found that despite continuous elevation of basal GH, the frequency and amplitude of pulsatile GH secretion were not significantly altered — suggesting that pulsatility persists even under sustained GHRH-analog stimulation ^[11]. This is a pharmacologically interesting finding, but it comes from a small study and does not resolve questions about long-term safety.

CJC-1295 administration also shifted the serum proteome in a small study of 11 healthy young men, reducing apolipoprotein A1 and a transthyretin isoform while increasing albumin-fragment and immunoglobulin species; the immunoglobulin/albumin signal correlated linearly with IGF-1, suggesting these as candidate biomarkers of GH/IGF-1 axis activation ^[9].

What the research shows

The honest characterization of the CJC-1295 evidence base is: early, small, and primarily pharmacokinetic. The human studies ^[10][11][9] establish that the compound does what its mechanism predicts — it raises GH and IGF-1 in a dose-related and sustained way, with pulsatility preserved. What they do not establish is whether that GH and IGF-1 elevation produces clinically meaningful benefits in any population, how safe it is over months or years, or what the right conditions for use would be if it were ever developed as a medicine.

The development program for CJC-1295 never reached approval. The original long-acting DAC program ran a Phase 2 trial in HIV-associated visceral obesity that was discontinued. A patient death during the development era is frequently cited alongside the halted program in online discussions. The public record does not establish a causal link between CJC-1295 and that death, and this desk reports that unresolved history accurately: the drug never advanced, and the reasons were not fully public.

A 2025 Nature Reviews Endocrinology review covers the GHRH-analog class including long-acting variants of this type, framing the therapeutic landscape and the evidence gaps ^[1]. For the most current regulatory signal, FDA's 2024 Pharmacy Compounding Advisory Committee briefing materials cited immunogenicity and safety concerns as grounds for not recommending CJC-1295 for the 503A compounding bulks list.

Most protocols circulating online for CJC-1295 are not derived from published controlled trials. The human data are limited to the early pharmacokinetic studies cited here.

Reported effects, cautions, and safety

The following community-reported effects are anecdotal, not clinical evidence. They come from peptide-user forums, wellness-clinic write-ups, and consumer guides — not controlled trials.

The most commonly reported benefit is deeper, more restful sleep, often described as the first noticeable change. This fits the biology: GH is released mainly during deep sleep. Faster recovery between workouts, gradual fat loss (particularly abdominal), a leaner appearance, and better muscle retention while dieting are frequently reported community themes. Some users describe improved daytime energy and sharper mental focus, usually attributed to better sleep. Firmer-feeling skin and connective-tissue improvements are occasionally mentioned. These are personal accounts, not measured outcomes.

On the adverse side, water retention and puffiness — particularly with the long-acting DAC form, which keeps IGF-1 elevated for days — is the most commonly reported downside, described as bloating and a heavier feeling around the face and hands. Tingling or numbness in the fingers (attributed to fluid retention pressing on nerves) is frequently reported and described as dose-related. Injection-site redness, itching, and soreness are common local effects. Brief flushing or a head-rush feeling after injecting, fatigue or drowsiness, mild headaches, and increased appetite (most often reported when CJC-1295 is combined with other compounds) are occasionally mentioned. Higher blood sugar or reduced insulin sensitivity is a cautionary signal, particularly for those with existing metabolic concerns.

Clinical safety considerations from the literature:

• Not approved for human use: CJC-1295 is a research chemical with no regulatory approval and a thin human evidence base ^[10][11].
• IGF-1 and cancer risk: Epidemiologic meta-analyses have linked higher circulating IGF-1 to modestly increased risk of certain cancers. Because the DAC form keeps IGF-1 elevated for days, a mechanism-based concern exists for people with a personal or family history of cancer.
• Fluid retention and nerve effects: GH promotes renal sodium and water retention, the likely mechanism behind reported edema and carpal-tunnel-like tingling — a real physiologic concern, not purely cosmetic ^[10].
• Glucose and insulin sensitivity: Sustained GH elevation is glucose-sparing, and GHRH-analog studies have documented effects on insulin sensitivity ^[15]. People with diabetes, prediabetes, or insulin resistance have particular reason for caution.
• Immunogenicity: FDA briefing materials cited immunogenicity as a safety consideration for this compound — a regulator-level concern that is unresolved in the public clinical literature ^[1].
• Discontinued development and unresolved safety history: The halted Phase 2 program and a patient death during the development era are part of the public record, even if causality was not established.
• DAC vs. no-DAC confusion: Treating the two forms as pharmacologically equivalent is a substantive error, not a terminology preference. Duration of IGF-1 elevation differs by orders of magnitude.
• Anti-doping prohibition: CJC-1295 is prohibited at all times under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is detectable with established LC-MS/MS assays.

Where it fits in the Growth Hormone Axis theme

CJC-1295 occupies the "what if you engineered for duration?" position in the GH-axis research landscape. Sermorelin is short-acting and structurally close to native GHRH; tesamorelin extends the full 44-residue sequence with a stability modification and has actual Phase 3 trial data for a specific clinical indication. CJC-1295 is the engineered long-duration variant — and the one with the thinnest regulatory and clinical record of the three.

The research story here is as much about what was not shown as what was. The pharmacokinetics are interesting. The clinical program was abandoned. The compound circulates widely in research communities despite this track record. This desk reports all of that. See the compare page for a direct three-way comparison, or read the Tesamorelin page for the GH-axis compound where the clinical trials were actually completed.